Hyperglycemia-induced podocyte detachment, hypertrophy, and effacement compromising the glomerular filtration barrier. SGLT2 inhibitors mitigate these effects by reducing intraglomerular pressure and preserving actin cytoskeleton integrity. Here, SLC5A2 is linked to Hyperglycemia.